Veracyte, Inc. (VCYT)

Market Cap	2.43B
Revenue (ttm)	463.39M
Net Income (ttm)	33.05M
Shares Out	77.94M
EPS (ttm)	0.41
PE Ratio	75.33
Forward PE	24.59
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,123,722
Open	30.19
Previous Close	30.84
Day's Range	27.24 - 31.57
52-Week Range	19.73 - 47.32
Beta	2.15
Analysts	Buy
Price Target	39.89 (+27.81%)
Earnings Date	May 7, 2025

About VCYT

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It is also developing the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Oct 30, 2013
• Employees: 824
• Stock Exchange: NASDAQ
• Ticker Symbol: VCYT
• Website: https://www.veracyte.com

Analyst Forecast

According to 9 analysts, the average rating for VCYT stock is "Buy." The 12-month stock price forecast is $39.89, which is an increase of 27.81% from the latest price.

Price Target

$39.89

(27.81% upside)

Analyst Consensus: Buy